Clinical Trials
22 trialsNCT04613596 2026-05-20
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Phase 2/3 Recruiting
NCT07415031 2026-05-15
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT06875310 2026-05-13
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
Phase 3 Recruiting
NCT04793958 2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT06497556 2026-04-20
Krascendo 1
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05853575 2026-03-27
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Active not recruiting
NCT05578092 2026-02-19
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT06764771 2025-12-17
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
NCT06039384 2025-08-03
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Incyte Corporation
Phase 1 Terminated
NCT06024174 2025-07-22
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT05375994 2025-05-18
RAMP204
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT05840510 2025-04-25
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT04330664 2025-04-04
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Mirati Therapeutics Inc.
Phase 1 Completed
NCT05178888 2025-02-11
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Mirati Therapeutics Inc.
Phase 1 Completed
NCT04685135 2025-01-22
KRYSTAL-12
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT04975256 2024-12-16
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT05924152 2024-03-13
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
Mirati Therapeutics Inc.
Phase 1 Completed
NCT05263986 2023-02-27
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1 Unknown